

A detailed illustration of a microbiome. It features a large, prominent red rod-shaped bacterium with numerous thin, red, hair-like flagella extending from its ends. This central bacterium is surrounded by a dense field of smaller, diverse microorganisms in various colors including blue, teal, black, and grey. The background is a light, neutral tone, making the colorful microbes stand out.

WHAT IS THE POWER OF THE MICROBIOME?

...AND CAN IT BE UNLOCKED
TO TREAT DISEASE?

Visit the Ferring virtual exhibit to explore the potential.

Ferring is shedding light on the link between disease and disruptions in the gut microbiome, exploring the potential for repopulating its diversity and restoring hope to patients. We are in the process of transforming the potential of microbiome restoration into novel live biotherapeutics and pioneering a category of microbiome-based therapeutics to help people live better lives and advance current standards of care. While we are starting with recurrent *C. difficile* infection, we believe this is only the beginning of how we harness the power of the microbiome to fight disease.



Microbiome
Therapeutics
Development





C. diff INFECTION RECURS
IN UP TO 35% OF PATIENTS^{1,2,a}

CAN YOU BREAK THE CYCLE WITH THE POWER OF THE MICROBIOME?

Visit the Ferring virtual exhibit to explore the potential.

Ferring is shedding light on the link between disease and disruptions in the gut microbiome, exploring the potential for repopulating its diversity and restoring hope to patients. We are in the process of transforming the potential of microbiome restoration into novel live biotherapeutics and pioneering a category of microbiome-based therapeutics to help people live better lives and advance current standards of care. While we are starting with recurrent *C. difficile* infection, we believe this is only the beginning of how we harness the power of the microbiome to fight disease.

^aWithin 8 weeks after initial *C. diff* infection diagnosis.¹

References: 1. Lessa FC, Mu Y, Bamberg WM, et al. Burden of *Clostridium difficile* infection in the United States. *N Engl J Med.* 2015;372(9):825-834. 2. Cornely OA, Miller MA, Louie TJ, Crook DW, Gorbach SL. Treatment of first recurrence of *Clostridium difficile* infection: fidaxomicin versus vancomycin. *Clin Infect Dis.* 2012;55(suppl 2):s154-s161.



Microbiome
Therapeutics
Development

